Clinical utility of denosumab for treatment of bone loss in men and women

References

• KhoslaSBurrDCauleyJBisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res200722101479149117663640
   PubMed Web of Science ®Google Scholar
• AbrahamsenBAdverse effects of bisphosphonatesCalcif Tissue Int201086642143520407762
   PubMed Web of Science ®Google Scholar
• ShaneEBurrDEbelingPRAtypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res201025112267229420842676
   PubMed Web of Science ®Google Scholar
• RizzoliRAkessonKBouxseinMSubtrochanteric fractures after long-term treatment with bisphosphonates: A European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group reportOsteoporos Int201122237339021085935
   PubMed Web of Science ®Google Scholar
• GreenJCzannerGReevesGWatsonJWiseLBeralVOral bisphosphonates and risk of cancer of esophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohortBMJ20101341
   Google Scholar
• CardwellCRAbnetCCCantwellMMMurrayLJExposure to oral bisphosphonates and risk of esophageal cancerJAMA2010304665766320699457
   PubMed Web of Science ®Google Scholar
• RheeCWLeeJOhSChoiNKParkBJUse of bisphosphonates and risk of atrial fibrillation in older women with osteoporosisOsteoporos Int3242011 [Epub ahead of print].
   Web of Science ®Google Scholar
• WattsNBDiabDLLong-term use of bisphosphonates in osteoporosisJ Clin Endocrinol Metab20109541555156520173017
   PubMed Web of Science ®Google Scholar
• SilvermanSLSchousboeJTGoldDTOral bisphosphonate compliance and persistence: A matter of choice?Osteoporos Int2011221212620458571
   PubMed Web of Science ®Google Scholar
• WilkesMMNavickisRJChanWWLewieckiEMBisphosphonates and osteoporotic fractures: A cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trialsOsteoporos Int201021467968819572092
   PubMed Web of Science ®Google Scholar
• PetkovVIWilliamsMIAdherence, compliance, and persistence with osteoporosis therapiesAdlerRAOsteoporosis Pathophysiology and Clinical Management2nd edNew York, NYHumana Press2010
   Google Scholar
• SirisESPasqualeMKWangYWattsNBEstimating bisphosphonate use and fracture reduction among US women aged 45 years and olderJ Bone Miner Res201126131120662073
   PubMed Web of Science ®Google Scholar
• HadjiPClausVZillerVIntorciaMKostevKSteinleTGRAND: The German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonatesOsteoporos Int2102011 [Epub ahead of print].
   Web of Science ®Google Scholar
• KostenuikPJNguyenHQMcCabeJDenosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKLJ Bone Miner Res2009242185195
   Web of Science ®Google Scholar
• Eghbali-FatourechiGKhoslaSSanyalABoyleWJLaceyDLRiggsBLRole of RANK ligand in mediating increased bone resorption in early postmenopausal womenJ Clin Invest200311181221123012697741
   PubMed Web of Science ®Google Scholar
• LiJSarosiIYanXQRANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolismProc Natl Acad Sci U S A20009741566157110677500
   PubMed Web of Science ®Google Scholar
• RossABBatemanTAKostenuikPJThe effects of osteoprotegerin on the mechanical properties of rat boneJ Mater Sci Mater Med200112758358815348250
   PubMed Web of Science ®Google Scholar
• HofbauerLCKhoslaSDunstanCRLaceyDLSpelsbergTCRiggsBLEstrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cellsEndocrinology199914094367437010465311
   PubMed Web of Science ®Google Scholar
• LewieckiEMTreatment of osteoporosis with denosumabMaturitas201066218218620236778
   PubMed Web of Science ®Google Scholar
• BaronRFerrariSRussellRGDenosumab and bisphosphonates: Different mechanisms of action and effectsBone201148467769221145999
   PubMed Web of Science ®Google Scholar
• DurgeRDawson-HughesBSolomonDHWongJBKingATostesonAIncidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025J Bone Miner Res200722346547517144789
   PubMed Web of Science ®Google Scholar
• MorinSLixLMAzimaeeMMetgeCCaetanoPLeslieWDMortality rates after incident non-traumatic fractures in older men and womenOsteoporos Int12162010 [Epub ahead of print].
   Web of Science ®Google Scholar
• HaentjensPMagazinerJColon-EmericCSMeta-analysis: Excess mortality after hip fracture among older women and menAnn Intern Med2010152638039020231569
   PubMed Web of Science ®Google Scholar
• MacLeanCNewberrySMaglioneMSystematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosisAnn Intern Med2008148319721318087050
   PubMed Web of Science ®Google Scholar
• RizzoliRBisphosphonates for post-menopausal osteoporosis: Are they all the same?QJM2011104428130021258058
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• BoonenSAdachiJDManZTreatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high riskJ Clin Endocrinol Metab3162011 [Epub ahead of print].
   Web of Science ®Google Scholar
• BlackDMSchwartzAVEnsrudKEEffects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trialJAMA2006296242927293817190893
   PubMed Web of Science ®Google Scholar
• BoneHGBologneseMAYuenCKEffects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone massJ Clin Endocrinol Metab201196497298021289258
   PubMed Web of Science ®Google Scholar
• BrownJPPrinceRLDealCComparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trialJ Bone Miner Res20091413420200996
   PubMedGoogle Scholar
• HochbergMCGreenspanSWasnichRDMillerPThompsonDERossPDChanges in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agentsJ Clin Endocrinol Metab20028741586159211932287
   PubMed Web of Science ®Google Scholar
• EastellRVrijensBCahallDLRingeJDGarneroPWattsNBBone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherenceJ Bone Miner Res212011 [Epub ahead of print].
   Web of Science ®Google Scholar
• ShahinianVBKuoYFFreemanJLGoodwinJSRisk of fracture after androgen deprivation for prostate cancerN Engl J Med2005352215416415647578
   PubMed Web of Science ®Google Scholar
• Lu-YaoGLAlbertsenPCMooreDFSurvival following primary androgen deprivation therapy among men with localized prostate cancerJAMA2008300217318118612114
   PubMed Web of Science ®Google Scholar
• AdlerRAManagement of osteoporosis in men on androgen deprivation therapyMaturitas201168214314721129866
   PubMed Web of Science ®Google Scholar
• FrenchDDBassEBradhamDDCampbellRRRubensteinLZRehospitalization after hip fracture: Predictors and prognosis from a national veterans studyJ Am Geriatr Soc200856470571018005354
   PubMed Web of Science ®Google Scholar
• GreenspanSLNelsonJBTrumpDLResnickNMEffect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trialAnn Intern Med2007146641642417371886
   PubMed Web of Science ®Google Scholar
• KimHSFreedlandSJAndrogen deprivation therapy in prostate cancer: Anticipated side-effects and their managementCurr Opin Support Palliat Care20104314715220592607
   PubMedGoogle Scholar
• SmithMRAndrogen deprivation therapy for prostate cancer: New concepts and concernsCurr Opin Endocrinol Diabetes Obes200714324725417940447
   PubMedGoogle Scholar
• SmithMRAndrogen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivorsCurr Urol Rep20089319720218765113
   PubMedGoogle Scholar
• SmithMREgerdieBHernandez TorizNDenosumab in men receiving androgen-deprivation therapy for prostate cancerN Engl J Med2009361874575519671656
   PubMed Web of Science ®Google Scholar
• BruderJMMaJZBaslerJWWelchMDPrevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapyUrology200667115215516413352
   PubMed Web of Science ®Google Scholar
• BoneHGBologneseMAYuenCKEffects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone massJ Clin Endocrinol Metab201196497298021289258
   PubMed Web of Science ®Google Scholar
• GrossmanJMGordonRRanganathVKAmerican College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosisArthritis Care Res2010621115151526
   PubMed Web of Science ®Google Scholar
• HansenKEFinkHMinisolaSWilsonHAZapalowskiCAdlerRAUncertainties in the prevention and treatment of glucocorticoid-induced osteoporosisJ Bone Miner Res2011 In press.
   Web of Science ®Google Scholar
• DoreRKCohenSBLaneNEEffects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonatesAnn Rheum Dis201069587287519734132
   PubMed Web of Science ®Google Scholar
• StopeckATLiptonABodyJJDenosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind studyJ Clin Oncol201028355132513921060033
   PubMed Web of Science ®Google Scholar